

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

Docket Number:  
**1662/63303**

Application Number  
**10/802,627**

Filing Date  
**March 17, 2004**

Examiner  
**Not Yet Assigned**

Art Unit  
**1614**

Invention Title  
**POLYMORPHS OF VALSARTAN**

Inventors  
**Rukhman, et al.**

**Address to:**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: 9/9/04

Signature: Agnes N. Xu  
Agnes N. Xu

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. In accordance with the Official Gazette of August 5, 2003, which stated that the United States Patent and Trademark Office waived the requirement under 37 C.F.R. § 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications filed after June 30, 2003, copies of each of the cited U.S. patents and U.S. patent application publications are not being provided.
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.

4. Applicant's attorney certifies that each item of information contained in the information disclosure statement was first cited in the International Search Report (copy attached) from PCT office in a counterpart foreign application not more than three months prior to the filing of information disclosure statement.
5. It is believed that no fees are due in connection with this Supplemental Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A copy of this communication is enclosed for charging purposes.


Dated: Sept 9, 04

By:

Payam Moradian  
Payam Moradian (Reg. No. 52,048)

KENYON & KENYON  
One Broadway  
New York, New York 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)  
CUSTOMER NUMBER 26646

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>PTO-1449</b>	ATTY. DOCKET NO. <b>1662/63303</b>	U.S. SERIAL NO. <b>10/802,627</b>
	APPLICANT(S) <b>Rukhman, et al.</b>	
	FILING DATE <b>March 17, 2004</b>	GROUP <b>1614</b>



### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 03/089417	October 30, 2003	PCT				
	WO 04/026847	April 1, 2004	PCT				

### OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Borka L., et al., "Crystal Polymorphism of Pharmaceuticals", <i>Acta Pharm. Jugosl.</i> , 40, (1990) 71-94

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	